|
|
|
| Effect of GnRH-a Combined with Intrauterine Placement of LNG-IUS on Postoperative Recurrence, Reproductive Hormone, Dysmenorrhea and Serum CA125 in Patients with EMT |
| ZHANG Juan, HAN Xiao-man, XIAO Min-su |
| Department of Obstetrics and Gynecology, Meixian People's Hospital, Baoji Shaanxi 722300 |
|
|
|
|
Abstract 【Objective】 To investigate the effects of gonadotropin releasing agonist (GnRH-a) combined with levonorgestrel intrauterine sustained release system (LNG-IUS) on postoperative recurrence, reproductive hormone, dysmenorrhea, and serum glycoprotein 125 (CA125) in patients with endometriosis (EMT) postoperatively. 【Methods】 A total of 107 patients with EMT who underwent laparoscopic resection were enrolled in the study. Patients were randomly divided into the observation group (n=53) and the control group (n=54). The observation group received a gonadotropin-releasing agonist (GnRH-a) for 3 cycles after surgery, and then LNG-IUS was placed in the uterus; while the control group only received GnRH-a for 3 cycles of treatment after operation. The degree of dysmenorrhea (VAS score), serum CA125, Estrogen (E2), follicle stimulating hormone (FSH) and luteinizing hormone (LH) were compared between the two groups before and after surgery. The incidence of recurrence were followed up for 24 months. 【Results】 The dysmenorrhea degree (VAS) of the observation group was lower than that of the control group at 3 months, 12 months and 24 months after operation (P<0.05). There was no significant difference in the levels of E2,FSH, and LH between the two groups before and after operation (P>0.05). There was no significant difference in serum CA125 levels between the two groups before surgery (P>0.05);12 months after surgery, the serum CA125 level of the observation group was lower than that of the control group (P<0.05). After 24 months of follow-up, the recurrence rate of the observation group was 1.87% (1/53) , which was lower than that of the control group (12.96%,7/54). The difference was statistically significant (χ 2=4.744, P<0.05).【Conclusion】 Intrauterine placement of LNG-IUS after EMT patients plays an important role in preventing recurrence, lowering serum CA125 level, and further alleviating dysmenorrhea.
|
|
Received: 18 October 2019
|
|
|
|
|
|
[1] 苏桂芳. 腹腔镜下异位病灶切除联合骶前神经阻断治疗子宫内膜异位症性盆腔痛的效果[J].医学临床研究, 2018, 35(8):1603-1605.
[2] 邓柳枝, 丁杰, 李小毛. 左炔诺孕酮宫内缓释系统治疗Ⅰ期子宫内膜癌成功1例[J].广东医学, 2017, 38(17):2744.
[3] 周敏, 张呈艳, 朱彩芳,等. 左炔诺孕酮宫内缓释系统治疗子宫内膜增生的临床疗效及对患者性激素和性激素受体水平的影响[J].中国妇幼保健, 2017, 32(8):1771-1773.
[4] 张雁. 左炔诺孕酮宫内缓释系统放置前应用促性腺激素释放激素激动剂对子宫腺肌症合并重度痛经及月经量的影响[J].安徽医药, 2017, 21(7):1311-1313.
[5] 王静, 董艳, 焦艳. GnRH-a治疗子宫内膜异位症对于患者FSH、E2 IL-18及TNF-α等的变化影响[J].浙江临床医学, 2017, 19(8):1424-1425.
[6] 王敏, 潘月, 罗汝琼. GnRH-a联合腹腔镜手术治疗卵巢子宫内膜异位症的疗效及对卵巢储备功能的影响[J].中国妇幼保健, 2018, 33(8):1742-1744.
[7] 刘华柳.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的效果[J].中国现代药物应用, 2017, 11(11):18-20.
[8] 李晓燕.左炔诺孕酮宫内缓释系统(曼月乐环)治疗子宫内膜增生的临床疗效分析[J].生殖医学杂志, 2017, 26(4):336.
[9] Teal SB, Turok DK, Chen BA, et al. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system[J].Obstet Gynecol,2018, 133(1):1-3.
[10] Darney PD.Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use[J].Contraception,2018, 97(3):210-212.
[11] Jewell T, Kanj RV, Mullins E, et al. Use of the levonorgestrel intrauterine system in the treatment of heavy menstrual bleeding in adolescents with hemostatic disorders[J].J Pediatr Adolesc Gynecol,2017, 30(2):271-273.
[12] 姜孝好, 张辉. 腹腔镜术联合GnRH-a对不孕患者卵巢功能的影响[J].中国数字医学, 2017, 12(7):25-28. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(3): 477-478. |
|
|
|
|
2021, Vol. 38 
